Virtus Health provides trading update for first ten months of FY2022

Virtus Health Limited (ASX: VRT) has provided trading update Q3FY22 trading update together with the current acquisition process underway. The Company also provided trading update for the performance of the first ten months to 30 April 2022 of the FY22 financial year.

VRT highlighted that underlying demand drivers for assisted reproductive services continues to assist the growth in the sector. However, it experienced several challenging market factors during FY2022. Despite these challenges and pressure of the Acquisition Process, VRT’s strategic initiatives coupled with the Precision Fertility™ Digital Platform progressed well during these 10 months.

During last 10 months, the Company noted a 3.9% drop in the Fresh cycle growth. Revenue growth was down 1.6% and EBITDA by 29.6%.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Suite 1A, Level 2, 802-808 Pacific Highway, Gordon NSW 2072, Australia | 1800 005 780 | info@kapitales.com.au